Tirzepatide anhedonia: three case reports

A 2026 case series describes three women who reported reduced motivation, emotional flatness, or loss of interest while taking tirzepatide for obesity. Their symptoms improved after clinicians reduced the dose, although one also received bupropion. The pattern is worth studying, especially because symptoms returned after one patient raised her dose again. It does not establish how often this happens or prove that tirzepatide caused every reported change^[1].

What the clinicians observed

The report covers women aged 36, 62, and 64 who had obesity and had lost substantial weight during tirzepatide treatment. All had reached 15 mg weekly. Two had no previous mood disorder. The 36-year-old had a history of depression and anxiety but described the new feeling as different from her earlier depression. The reported problems included less desire to exercise, reduced interest in hobbies, and a general sense of feeling flat^[1]. These accounts came from clinical interviews rather than a validated symptom questionnaire.

The timing differed between patients. The first two sought care because they noticed the change. The third briefly stopped tirzepatide for a medical procedure and only recognized the contrast after restarting at a lower dose. The authors say they considered other possible explanations such as hormonal problems, anaemia, nutritional deficiencies, sleep disturbance, and broader signs of depression. The paper does not provide a randomized comparison or enough patients to show that this screening excluded every alternative cause^[1].

What changed after the dose was reduced

Patient 1 moved from 15 mg to 10 mg weekly for four months and reported marked improvement in exercise drive and interest in hobbies. She later raised the dose herself, first to 12.5 mg and then to 15 mg. The motivation problem returned without further weight loss. After clinician-led reductions to 10 mg and then 5 mg, she reported full resolution while maintaining her earlier weight loss^[1]. That recurrence after re-exposure makes the observation more suggestive, but one person's course cannot establish a dose-response relationship for other patients.

Patient 2 reported partial improvement after four weeks at 10 mg. Her clinicians then prescribed bupropion, so the later improvement cannot be assigned to the tirzepatide reduction alone. Patient 3 resumed treatment at 7.5 mg after a temporary interruption and noticed better motivation within two weeks. She maintained that dose for three months, with weight maintenance and improved engagement in daily activities^[1]. These are treatment histories, not instructions. Dose changes and antidepressant use require individual clinical assessment.

Why this is a signal, not a side-effect rate

A case series begins with selected patients who already had an unusual outcome. It cannot tell us the denominator: how many people used tirzepatide at similar doses without these symptoms. It also cannot compare symptom rates with placebo or another medicine. The authors identify the same limitations, including the three-person sample, lack of a control group, individual differences, and use of clinical history instead of a standardized instrument^[1]. The report can generate a research question. It cannot calculate incidence or relative risk.

The patients also entered the report through an online clinic. Two were already concerned about lost motivation, while one recognized it retrospectively after an interruption. That route may make the cases useful for description while limiting generalizability. The paper reports written consent and no external funding. It also discloses that two authors were full-time employees of Vineyard Health, one was a part-time employee, and one author had advised Novo Nordisk^[1]. Those disclosures do not invalidate the cases, but readers should have them when weighing the interpretation.

The proposed reward-pathway explanation

The authors propose that GLP-1-related effects on reward processing and dopamine circuits could contribute to reduced wanting or motivation. They discuss preclinical findings and emerging human work on reward-related behaviour. The paper also acknowledges mixed experimental findings, including studies showing nominal or increased dopamine responses in some tasks^[1]. This makes the mechanism plausible enough to test, not demonstrated in these patients. The case series did not measure dopamine activity or brain circuitry.

Anhedonia also overlaps with depression, medication effects, sleep problems, undernutrition, fatigue, and other medical conditions. The authors tried to distinguish the reported experience from depression, but the lack of a standardized instrument leaves uncertainty about exactly what was measured. Anyone experiencing a loss of pleasure, major mood change, or impaired daily function should seek qualified clinical assessment rather than self-diagnose a reward-circuit effect. General prescription context is available in the current Zepbound labelling^[2], while our tirzepatide safety overview explains the wider evidence base.

What we do not yet know

We do not know how common anhedonia-like symptoms are among people taking tirzepatide, whether risk changes reliably with dose or treatment duration, or which patients might be more susceptible. We also do not know whether the reported changes were specific to tirzepatide or could occur across the GLP-1 medicine class. The three cases cannot separate a medicine effect from weight-loss physiology, changing nutrition, expectations, or other care^[1].

A useful next study would recruit patients before treatment, measure motivation and pleasure with validated tools, and repeat those measures at prespecified times. It would need enough participants to estimate frequency and examine dose, duration, mood history, and concurrent medicines without turning a few observations into a general rule. Until then, the careful reading is narrow: three patients improved after individualized treatment changes, with one informative recurrence after re-escalation. The report supports awareness and further study. It does not support changing a prescription without the clinician managing it. See the tirzepatide evidence page for established trial and safety context.